Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2001; 47(6): 30-34


The content of biopolymers in the rat prostate under combinedagonist lh-releasing hormone and androgen receptor blocker treatment

O.V. Sachinska

    V.P.Komissarenko Institute of Endocrinology andMetabolism of Academy of Medical Sciences ofUkraine, Kiеv


Abstract

The effects of androgen receptor blocker Flutamide (Niftolide) and/or LH-releasing hormone agonist Sur- fagon on the nucleic acids and protein contents in the ventral prostate of male rats were studied. It was shown that combined drug treatment led to potentiating of “antiprostatic” effects of both preparations resulted in significant decrease of DNA, RNA and protein contents.

References

  1. СПИСОК ЛІТЕРАТУРИ
  2. Возианов А.Ф., Резников А.Г., Клименко И.А.Эндокринная терапия рака предстательной же-лезы. - К.: Наук. думка,1999. - 280 с.
  3. Резников А.Г., Варга С.В. Антиандрогены. – М.:1988. – 208 с.
  4. Розен В.Б. Основы эндокринологии. - М.: Высш.школа, 1984. - 336 с.
  5. Шаткин А. Колориметрические методы определе-ния ДНК, РНК и белка. – В кн.: Методы виру-сологии и молекулярной биологии /Ред. К.Ха-бель, М.П.Зальцман. - М.: Мир, 1972. - С. 84-89.
  6. Braden T.D., Conn P.M. Gonadotropin-releasinghormone and its action // Can. J. Physiol. Phar-macol. -1991. - 69, N 4. - P. 445-458.
  7. Furr B.J.A., Woodburn J.R. Luteinizing hormone-releasing hormone and its analogues: a review ofbiological properties and clinical uses // J. Endo-crinol. Invest. - 1988. - 11, N11. - P. 535-557.
  8. Labrie F., Dupont A., Cusan L. et al. Combinationtherapy with flutamide and castration (LHRHagonist or orchiectomy) in previously untreatedpatients with clinical stage D2 prostate cancer:today’s therapy of choice // J. Steroid Biochem. -1988. - 29. - P. 385-396.
  9. Sciarra F., Toscano G., Di Silverio F. Antian-drogens: clinical applications // J. Steroid Bio-chem. - 1990. - 37, N 3. - P 349-362.
  10. 9. Vacher P. Gn-RH agonists in the treatment ofprostatic carcinoma// Biomedicine and Phar-macotherapy. - 1995. - 49, N 7-8. - P. 325-331.
  11. 10. Wajsman Z. Arguments for the long-term use ofcombined androgen blockade // Eur. Urol. - 1998. -34. - Suppl 3. - Р 25-28.О. В. Сачинська
  12. 34 ISSN 0201-8489 Фізіол. журн., 2001, Т. 47, № 6
  13. Waxman J.H., Sandow J., Abel P. et al. Tow monthlydepot gonadotropin- releasing hormone agonist(buserelin) for treatment of prostatic cancer // ActaEndocrinol. - 1989. - 120, N 3. - P. 315-318.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2018.